Glenmark Pharmaceuticals Ltd. - Research Center
532296 GLENMARK Group (A) BSE data
Add to watchlist
| Results |
Quarterly
|
| Statement | |
| More |
Quarterly results in brief
(Rs crore)
| Mar' 24 | Dec' 23 | Sep' 23 | Jun' 23 | Mar' 23 | |
|---|---|---|---|---|---|
| Sales | 2,148.22 | 1,365.10 | 2,233.42 | 2,144.38 | 1,939.05 |
| Operating profit | 497.45 | -184.27 | 470.85 | 485.00 | 217.67 |
| Interest | 83.39 | 73.60 | 58.19 | 61.93 | 58.86 |
| Gross profit | 1,200.33 | 0.94 | 458.88 | 472.42 | 391.78 |
| EPS (Rs) | 163.50 | -0.72 | 10.72 | 9.63 | -4.87 |
Quarterly
results in details
| Mar' 24 | Dec' 23 | Sep' 23 | Jun' 23 | Mar' 23 | |
|---|---|---|---|---|---|
| Other income | 786.27 | 258.82 | 46.22 | 49.36 | 232.97 |
| Stock adjustment | -2.12 | -83.94 | 6.08 | -23.08 | -6.43 |
| Raw material | 685.45 | 701.17 | 807.03 | 796.76 | 777.09 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 337.75 | 379.56 | 383.00 | 334.47 | 306.12 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 629.70 | 552.57 | 566.46 | 551.25 | 644.60 |
| Provisions made | - | - | - | - | - |
| Depreciation | 52.40 | 51.16 | 49.85 | 48.75 | 46.73 |
| Taxation | 1,681.15 | -55.09 | 87.01 | 120.39 | -175.86 |
| Net profit / loss | 4,613.70 | -20.41 | 302.35 | 271.66 | -137.47 |
| Extra ordinary item | 5,146.91 | -25.28 | -19.67 | -31.63 | -658.37 |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 23.16 | -13.50 | 21.08 | 22.62 | 11.23 |
| GPM (%) | 40.90 | .06 | 20.13 | 21.54 | 18.04 |
| NPM (%) | 157.22 | -1.26 | 13.26 | 12.38 | -6.33 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis